Biotech entity
All 3 tracked stories fall under one category: pharma. Merck is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Source depth averages 4.3 original sources per story, versus 3.4 across the same-window beat baseline. The 13-day window averages about 1.6 stories each week.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: pharma. Merck is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Source depth averages 4.3 original sources per story, versus 3.4 across the same-window beat baseline. The 13-day window averages about 1.6 stories each week. The 5.3 average consequence score is below the beat benchmark of 6.1 in the same window. Codexis appears in 3 tracked Biotech stories published from March 12, 2026 through March 24, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 200 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Codexis. Shared-story counts are live from our verified record — not editorial picks.
Analyst Sentiment Review
Major firms maintain ratings, citing steady execution of the strategic pivot.
2026 Guidance Issued
Management outlines $72M-$76M revenue target driven by ECO Synthesis.
Q4 2025 Earnings Release
Codexis reports significant beats on both top and bottom lines.
Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Source: finance.yahoo.com · insidermonkey.com
Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Source: dailypolitical.com · themarketsdaily.com
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
Codexis is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
